COSCIENS Biopharma Inc. filings document a foreign private issuer reporting on Form 6-K and related U.S. disclosure obligations for its common shares. The company’s regulatory record includes material-event reports, notices for annual and special shareholder meetings, management proxy circular materials, and disclosures tied to capital-structure and shareholder voting matters.
Filings also cover governance, risk factors, operating and financial results, material agreements, and clinical or regulatory disclosures connected to COSCIENS’ life science business, including natural active ingredients and diagnostic-product activities. The records frame corporate-status matters such as Nasdaq delisting and U.S. reporting obligations through formal securities-law documents.
COSCIENS Biopharma Inc. filed a report to share a press release responding to unusual trading in its shares. The company states it is not aware of any material undisclosed information that would explain the recent increase in trading volume and price of its common stock.
The filing also repeats extensive forward-looking statement cautions, highlighting risks tied to potential insolvency proceedings of its German subsidiaries, development and commercialization of its patented natural active ingredients, liquidity and capital resources, and internal controls. COSCIENS describes itself as a life science company focused on plant-based ingredients used in skincare products.
COSCIENS Biopharma Inc., a Canada-based company listed on the TSX and OTCQB, files its annual Form 20-F for the year ended December 31, 2025. The company had 3,183,330 Common Shares outstanding as of December 31, 2025.
COSCIENS focuses on oat-based cosmeceutical and nutraceutical ingredients (including oat beta-glucan and avenanthramides) and on commercializing its licensed PGX Technology for processing biopolymers into high-value materials. A large majority of current revenue comes from a single distribution partner, Symrise AG, under an exclusive supply and distribution agreement that runs to December 31, 2026.
The filing highlights substantial risk, including a disclosed substantial doubt about the company’s ability to continue as a going concern, heavy reliance on Symrise AG for over 84% of revenues, significant financing needs, and exposure to tariffs, raw-material supply disruptions and intense competition. COSCIENS is also managing insolvency proceedings for its German subsidiaries, which may lead to surrendering rights to Macrilen and potential non-cash accounting impacts. Additional risks include possible PFIC tax status for U.S. holders, volatility in its share price, potential TSX delisting, cybersecurity threats, environmental obligations, and prior material weaknesses in internal controls that the company reports as remediated in 2025.
COSCIENS Biopharma Inc. reported a smaller loss for 2025 while making significant strategic changes. Full-year revenue was $7.5 million, down from $9.6 million, but the net loss narrowed to $10.4 million from $15.3 million as operating expenses fell to $13.3 million from $23.0 million.
In Q4 2025, revenue declined to $1.8 million from $3.3 million, yet the quarterly net loss improved to $2.2 million from $6.7 million, driven mainly by lower R&D and impairment charges. Cash and cash equivalents were $7.3 million at December 31, 2025.
The company decided to stop funding its German subsidiaries that house its biopharmaceutical business, including Macrilen, and an insolvency application was filed in Germany. COSCIENS expects about $1.9 million in annualized cost savings and for the German subsidiaries’ liabilities, including $11.0 million of unfunded pension obligations, to drop from its future financial statements. It also plans to seek termination or suspension of its U.S. Exchange Act reporting while maintaining Canadian reporting and TSX/OTCQB listings.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.